Citalopram reverses REM sleep deprivation-induced hyperlocomotion, pain hypersensitivity, and BDNF downregulation in rats
Background
Rapid-eye movement (REM) sleep deprivation (REM SD) significantly impairs cognitive and affective functions, yet findings across studies are often inconsistent. This critical sleep stage is vital for memory formation, consolidation, and mood regulation. A key protein, brain-derived neurotrophic factor (BDNF), is deeply involved in memory and mood processes, and its expression can be influenced by REM SD. Current therapeutic strategies for REM SD-induced deficits are limited, highlighting a need for interventions that can mitigate these neurobiological consequences.
Study Design
Researchers investigated the effects of REM SD (6 h/day for 7 days) on behavioral and cognitive performance in rats. The study also measured prefrontal cortex BDNF levels and serum oxidative stress markers, catalase (CAT) and malondialdehyde (MDA). A therapeutic intervention arm evaluated citalopram 20 mg/kg administered intraperitoneally (i.p.) for 7 days. Behavioral assessments included locomotor activity, rearing behavior, passive avoidance memory, and pain threshold. The control group received REM SD without citalopram treatment.
Results
REM SD significantly increased locomotor activity and rearing behavior in rats. It also impaired passive avoidance memory and reduced the pain threshold, indicating increased pain hypersensitivity. Furthermore, REM SD led to a downregulation of prefrontal BDNF expression. Interestingly, serum CAT and MDA levels, markers of peripheral oxidative stress, remained unchanged across groups, suggesting they do not play a major role in this specific paradigm. Citalopram treatment successfully reversed the REM SD-induced hyperlocomotion and increased rearing behavior. It also ameliorated the pain hypersensitivity and restored BDNF expression towards normal levels. However, citalopram did not significantly improve the memory impairment caused by REM SD, nor did it alter depressive-like behavior, which remained unchanged across all experimental groups. This suggests a selective therapeutic effect.
Citalopram treatment reversed REM SD-induced hyperlocomotion, increased rearing, pain hypersensitivity, and
BDNFdownregulation.
Key Findings
- REM SD increased locomotor activity and rearing behavior in rats.
- REM SD impaired passive avoidance memory and reduced pain threshold.
- REM SD downregulated prefrontal
BDNFexpression. - Citalopram 20 mg/kg reversed REM SD-induced hyperlocomotion and increased rearing.
- Citalopram reversed REM SD-induced pain hypersensitivity and
BDNFdownregulation.
Why It Matters
This study highlights citalopram's potential to mitigate specific behavioral and neurobiological deficits associated with REM sleep deprivation, particularly hyperlocomotion, pain hypersensitivity, and BDNF downregulation. For individuals experiencing chronic sleep deprivation, this suggests a possible pharmacological avenue to address certain symptoms, though not all. The finding that BDNF modulation underlies both the detrimental effects of REM SD and citalopram's therapeutic actions points to BDNF as a critical target for future interventions. However, the lack of improvement in memory and depressive-like behavior indicates that a comprehensive approach to REM SD consequences may require multi-target strategies. This preclinical data is a foundational step, but human clinical trials are needed before any practical protocols can be considered.
citalopram
rem-sleep-deprivation
bdnf
memory
mood
oxidative-stress